← All countries · Western Pacific
95%
MCV1
2025 · WHO/UNICEF estimate
95%
DTP3
2025 · WHO/UNICEF estimate
95%
IPV complete
2025 · WHO/UNICEF estimate
95%
HepB3
2025 · WHO/UNICEF estimate
917
Measles cases
2025 reported
133
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 98%2025 · WHO/UNICEF estimate | 98.3% | B · good | |
| DTP1First dose of diphtheria-tetanus-pertussis | 95%2025 · WHO/UNICEF estimate | 94.5% | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 95%2025 · WHO/UNICEF estimate | 94.8% | B · good | |
| IPV1First dose of inactivated polio vaccine | 95%2025 · WHO/UNICEF estimate | 94.5% | B · good | |
| IPV completeInactivated polio vaccine, complete primary series | 95%2025 · WHO/UNICEF estimate | 94.5% | D · poor | |
| MCV1First dose of measles-containing vaccine | 95%2025 · WHO/UNICEF estimate | 95.2% | B · good | |
| MCV2Second dose of measles-containing vaccine | 84%2025 · WHO/UNICEF estimate | 84.3% | B · good | |
| RCV1First dose of rubella-containing vaccine | 95%2025 · WHO/UNICEF estimate | 95.2% | B · good | |
| HepB3Third dose of hepatitis B vaccine | 95%2025 · WHO/UNICEF estimate | 0% | C · weak | |
| HepB birthHepatitis B birth dose within 24 hours | 92%2025 · WHO/UNICEF estimate | 92.1% | B · good | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 95%2025 · WHO/UNICEF estimate | 94.8% | B · good | |
| PCV1Pneumococcal conjugate vaccine, first dose | 92.7%2025 · Administrative (country-reported) | 92.7% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 93%2025 · WHO/UNICEF estimate | 92.9% | C · weak | |
| RotaCRotavirus vaccine, complete series | —% · Administrative (country-reported) | — | too few points | no data |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | 96.0%2019 · Administrative (country-reported) | 96.0% | D · poor | |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 96%2024 · WHO/UNICEF estimate | — | C · weak | |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 81%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 81%2025 · WHO/UNICEF estimate | — | C · weak | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | —% · Administrative (country-reported) | — | too few points | no data |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 9172025 | 25.5per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 882025 | 2.4per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 02024 | 0per 10,000 live births | D · poor | |
| Mumps all countries · vaccine evidence | 02023 | 0per 1,000,000 total population | D · poor | |
| Pertussis (whooping cough) all countries · vaccine evidence | 1332025 | 3.7per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 212025 | 0.6per 1,000,000 total population | A · strong | |
| Tetanus (total) all countries · vaccine evidence | 512025 | 1.4per 1,000,000 total population | A · strong | |
| Neonatal tetanus all countries · vaccine evidence | 182025 | 0per 1,000 live births | A · strong | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02024 | 0per 1,000,000 total population | B · good | |
| Japanese encephalitis all countries · vaccine evidence | 182025 | 0.5per 1,000,000 total population | A · strong | |
| Invasive meningococcal disease all countries · vaccine evidence | 02023 | 0per 1,000,000 total population | D · poor | |
| Typhoid all countries · vaccine evidence | 822025 | 2.3per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (32 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | General/routine | |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 5 | Y7 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M2 | General/routine | From November 2020 onwards |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | M3 | General/routine | From November 2020 onwards |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M5 | General/routine | From November 2020 onwards |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 4 | M18 | General/routine | From November 2020 onwards |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Health workers | HCWs |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Health workers | HCWs |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Health workers | HCWs |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | Until November 2020. From November 2020 onwards, only Hep B borth dose given. Subsequent doses given as hexavalent vaccine |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 1 | Y13 | HPV for females only | Given to female students only as part of School Health programme. One dose. |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| JE_LIVEATDJE-Livatd (Japanese Encephalitis live-attenuated) vaccine | 1 | M9 | General/routine · SUBNATIONAL | Sarawak state only |
| JE_LIVEATDJE-Livatd (Japanese Encephalitis live-attenuated) vaccine | 2 | M21 | General/routine · SUBNATIONAL | Sarawak state only |
| MEASLESMeasles vaccine | 1 | M6 | General/routine · SUBNATIONAL | Sabah state only |
| MEN_ACYW_135PSMeningococcal ACYW polysaccharide vaccine | 1 | Risk group(s) | Hajj pilgrims only | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M9 | General/routine | children born July 2015 onwards |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | M12 | General/routine | children born July 2015 onwards |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | Catch-up children | From 1 December 2020 onwards with catch-up vaccination for children born from 1 January 2020 onwards | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | M4 | General/routine | From 1 December 2020 onwards with catch-up vaccination for children born from 1 January 2020 onwards |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | M6 | General/routine | From 1 December 2020 onwards with catch-up vaccination for children born from 1 January 2020 onwards |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M15 | General/routine | From 1 December 2020 onwards with catch-up vaccination for children born from 1 January 2020 onwards |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | Pregnant women 2nd and 3rd trimester 28-32 weeks | |
| TTTT (Tetanus toxoid) vaccine | 1 | Pregnant women | Pregnant women (2nd and 3rd trimester) | |
| TTTT (Tetanus toxoid) vaccine | 6 | Y15 | General/routine | |
| TYPHOID_PSTyphoid polysaccharide vaccine | 1 | 1st contact | Risk group(s) | All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years |
| TYPHOID_PSTyphoid polysaccharide vaccine | 2 | +Y3 | Risk group(s) | All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.